Pharmaron Beijing Co., Ltd — Board/Management Information 2020

Jul 10, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [117 x 33] intentionally omitted <==

Pharmaron Beijing Co., Ltd. 康龍化成（北京）新藥技術股份有限公司*

(a joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 3759)

ANNOUNCEMENT OF THE APPOINTMENT OF THE EMPLOYEE REPRESENTATIVE SUPERVISOR

Reference is made to the announcement of Pharmaron Beijing Co., Ltd.* (康龍化成（北京）新藥技 術股份有限公司) (the “ Company ”) dated June 24, 2020 in relation to, among others, the proposed appointment of the Supervisors for the Second Session of the Supervisory Committee.

On July 10, 2020, the employee representatives’ meeting of the Company re-elected Ms. ZHANG Lan (“ Ms. ZHANG ”) as the employee representative Supervisor for the Second Session of the Supervisory Committee. The term of office of the employee representative Supervisor for the Second Session of the Supervisory Committee is three years, which is the same as the term of office of the Second Session of the Supervisory Committee. Similar with the arrangement for the other Supervisors of the Second Session of the Supervisory Committee, the Company will enter into a service contract with Ms. ZHANG in her role as the employee representative Supervisor. Ms. ZHANG shall not receive any remuneration for her role as the employee representative Supervisor. The Company will reimburse the Supervisors all necessary and actual expenses in relation to the participation of Board meetings, the Board committee meetings, the meetings of the Supervisors and the general meeting of shareholders.

The biographical details of Ms. ZHANG are as follows:

Ms. ZHANG Lan (張嵐), aged 38, has been appointed as the employee representative Supervisor since October 27, 2016 and is primarily responsible for the supervision of the performance of the Directors and senior management members. Ms. ZHANG joined our Group on April 5, 2006 and currently serves as our associate director. As of the date of this announcement, Ms. ZHANG is indirectly interested in 56,865 A shares of the Company, representing approximately 0.007% of the issued share capital of the Company.

Ms. ZHANG obtained her bachelor’s degree in English at Tangshan Teacher’s College (唐山師範 學院) in Hebei, China in June 2005.

Saved as disclosed above, as of the date of this announcement, Ms. ZHANG does not have any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years or any other major appointments and professional qualifications and she (i) is not related to any Directors, Supervisors, senior management or substantial Shareholders; (ii) is not interested in any shares of the Company within the meaning of Part XV of the SFO; or (iii) does not hold any other position with the Company or other members of the Group.

1

Saved as disclosed above, as of the date of this announcement, Ms. ZHANG has confirmed that there are no matters that need to be brought to the attention of the Shareholders and there is no other information in relation to the proposed appointment of her that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

By order of the Board Pharmaron Beijing Co., Ltd. 康龍化成（北京）新藥技術股份有限公司* Chairman Dr. Lou Boliang

Beijing, the PRC July 10, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Li Lihua, Ms. Chen Guoqin, Ms. Shen Rong and Mr. Tsang Kwan Hung Benson as independent non-executive Directors.

• For identification purposes only

2